Announcement PDF 1 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Annual General Meeting 2025 Acrux Ltd (ASX:ACR) | 25 November 2025 2 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Disclaimer This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Actual results could differ materially depending on factors such as the availability of resources, the results of non-clinical and clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of our Company, the Directors and our management. We cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements. We have no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation, except where required by law and under our continuous disclosure obligations. These forward-looking statements are subject to various risk factors that could cause our actual results to differ materially from the results expressed or anticipated in these statements. 3 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 John Warmbrunn B.Sc. M.B.A. G.A.I.C.D CEO & Managing Director Appointed June 2025 4 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Our Vision & Mission Our Vision Acrux is a dynamic Australian drug delivery company developing and commercialising patient preferred healthcare products for global markets Our Mission Economic value at Acrux is created by talented people who effectively develop and commercialise healthcare products using invented or acquired technologies Acrux’s products are patient- preferred, protected by patent or other means, using innovative drug delivery 5 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Drug Development Pedigree + Substantial Knowhow and IP Our Blockbuster Heritage Acrux Platform Applicator + Delivery Method + Enhancers Axiron® US approval in 2010 2000 2006 2001 2002 2005 ® ® ® References: Bloomberg; Pharma Letter; Sydney Morning Herald; Company Data 6 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Finding a Blockbuster Sequel What I expected to find: Generic What I actually found: Extensions and Knowhow Hormone Replacement Therapy (HRT) 7 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Innovative Skin Delivery Technology Innovative Skin Delivery Technology Design capabilities, intellectual property, and knowhow accumulated over 25 years Generics Strategy (focus for past decade) • Innovation • Devices • Registration • Transdermal delivery • Topical Assets in advanced R&D stage • Innovation • Devices • Registration • Transdermal delivery • Topical Innovation Devices Registration Transdermal delivery Topical • HRT • New applications of Acrux R&D 8 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Near Term Focus: Strategic Review Generics Strategy FDA/EU/TGA pathways for HRT Technology pathways for new application of R&D products 3 complimentary, strategic pathways progressing Regulatory hurdles Investment milestones Size of opportunity Technical assessment Viability of faster investment milestones Size of opportunity Regulatory hurdles Development portfolio Broadening commercialised portfolio to global markets 9 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Upcoming Activities Completed Activities Developing Parallel Strategies Generics Strategy New application of R&D HRT Define FDA Pathway Tech Transfer Registration Licensing Expand into international markets 5 x commercialised products Development portfolio pipeline R&D Clinical trials Historic R&D R&D Tech Transfer Strategic Review Commercialisation of development portfolio Quicker to market Registration Commercial 10 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Successfully Bringing Generics to Market Powerful partnerships Proven product portfolio Infrastructure & capabilities Experienced team First licenced product in Saudi Arabia Nitroglycerine 0.4% ointment launched Dapsone 5% gel launched Dapsone 7.5% gel launched Prilocaine 2.5% & Lidocain 2.5% cream Evamist® royalties continue FDA registered products commercialised in the US 11 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Current strategy targets niche categories (US topical generics) with high barriers to entry Generic Market Trends US generic marketplace trends • Incursion by mainstream and specialist generic companies • Market advantage more difficult to achieve • More competition suppressing average selling prices • Range of attractive US niches becoming more limited Careful consideration of portfolio based on market conditions and forecast ROI 12 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 International Portfolio Realisation Leverage existing FDA registration (attractive categories only) UK IRL pathway offers faster and more certain registration pathway Saudi Arabia example of local partners ability to leverage FDA registration Our regulatory skills and knowledge support future, global registrations. Leverages FDA registration. 13 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Generic Portfolio Revenue Performance $0.863m FY25 FY26 License revenue from Generic Portfolio ($m) Q1 Q2 Q3 Q4 License revenue in Q1 2026 is greater than all of FY2025 +449% y-o-y 14 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Summary Broadening topical generics licensing is generating global revenue New applications of Acrux R&D under review New strategy being validated to prioritise options Consideration for balancing capital between generics and other strategic options 15 Acrux Ltd (ASX:ACR) | Annual General Meeting | 25 November 2025 Connect with us info@acrux.com.au www.acrux.com.au +61 3 8379 0100